Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6268Carcinoma, Renal Cell 1913Urinary Bladder Neoplasms 1670Kidney Neoplasms 930Breast Neoplasms 793Neoplasms 788Carcinoma, Transitional Cell 594Carcinoma, Non-Small-Cell Lung 524Neoplasm Metastasis 510Melanoma 485Ovarian Neoplasms 468Colorectal Neoplasms 454Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 267Uterine Cervical Neoplasms 264Non-Muscle Invasive Bladder Neoplasms 263Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 197Wilms Tumor 196Endometrial Neoplasms 189Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 146

Interventions

rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ATM Gene Mutation × Genitourinary × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡